Stock Research: Theravance Biopharma

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Theravance Biopharma

NasdaqGM:TBPH KYG8807B1068
48
  • Value
    42
  • Growth
    89
  • Safety
    Safety
    19
  • Combined
    49
  • Sentiment
    50
  • 360° View
    360° View
    48
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Theravance Biopharma is a biopharmaceutical company focused on developing medicines for respiratory and neurologic diseases. It operates in the biopharmaceutical industry. Its product, YUPELRI, is used for treating chronic obstructive pulmonary disease (COPD). In the last fiscal year, the company had a market cap of $579 million and a revenue of $64 million, with 97 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 48 (better than 48% compared with alternatives), overall professional sentiment and financial characteristics for the stock Theravance Biopharma are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Theravance Biopharma. The consolidated Growth Rank has a good rank of 89, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 89% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 50, which means that professional investors are more optimistic about the stock than for 50% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 19, which means that the share price of Theravance Biopharma is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 81% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 42, which means that the company has a financing structure that is riskier than those of 58% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
19 7 29 25
Growth
89 55 61 83
Safety
Safety
42 40 74 17
Sentiment
50 21 20 10
360° View
360° View
48 8 37 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
62 55 77 5
Opinions Change
63 50 50 50
Pro Holdings
n/a 15 1 82
Market Pulse
21 22 13 7
Sentiment
50 21 20 10
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
19 7 29 25
Growth
89 55 61 83
Safety Safety
42 40 74 17
Combined
49 8 67 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
7 1 11 11
Price vs. Earnings (P/E)
9 15 7 1
Price vs. Book (P/B)
78 60 68 100
Dividend Yield
1 1 1 1
Value
19 7 29 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
4 100 96 94
Profit Growth
96 26 4 72
Capital Growth
94 9 99 95
Stock Returns
97 65 31 3
Growth
89 55 61 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
47 50 100 1
Refinancing
94 78 94 94
Liquidity
1 1 1 1
Safety Safety
42 40 74 17

Similar Stocks

Discover high‑ranked alternatives to Theravance Biopharma and broaden your portfolio horizons.

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Colbún

SNSE:COLBUN
Country: Chile
Industry: Power Producers & Traders
Size: Medium
Full Stock Analysis

Sonatel

BRVM:SNTS
Country: Senegal
Industry: Integrated Telecommunication
Size: Medium
Full Stock Analysis

Lojas Renner

BOVESPA:LREN3
Country: Brazil
Industry: Apparel Retail
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.